An interventional study of DAISe in Stroke, Acute Ischemic, sponsored by MIVI Neuroscience, Inc.. Terminated at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by MIVI Neuroscience, Inc. · Not applicable, Interventional, and Treatment
This study is to assess initial safety and performance data of the DAISe Thrombectomy Device for removal of thrombus during an acute ischemic stroke.
2,653 studies on the registry are indexed under Ischemic Stroke; 936 are open to participants now.
This study's enrollment of 2 is below the median of 120 across 1,799 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →MIVI Neuroscience, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
DAISe Thrombectomy Device
Device: DAISe
Use of the DAISe Thrombectomy Device
Rate of Successful Revascularization
mTICI (Modified TICI) 2b-3 of the target vessel post-treatment with the DAISe Thrombectomy Device
Time frame: Procedure
Rate of Symptomatic Intracranial Hemorrhage
Time frame: 24 hours post-procedure
Rate of Procedure related Complications
Time frame: Through 90 day post-procedure
Occurrence of all intracranial hemorrhage
Time frame: 24 hours post-procedure
All-cause mortality
Time frame: Through Acute Hospital Discharge
Embolization to a New Vascular Territory
Time frame: Procedure
Successful Revascularization after first attempt with DAISe
mTICI (modified TICI) 2b-3 after first pass with device
Time frame: Procedure
Successful Revascularization after first attempt with DAISe
mTICI (modified TICI) 2c-3 after first pass with device
Time frame: Procedure
Successful Revascularization at end of procedure
mTICI (modified TICI) 2b-3 at the end of procedure
Time frame: Procedure
Successful Revascularization at end of procedure
mTICI (modified TICI) 2c-3 at the end of procedure
Time frame: Procedure
Ran from Jun 2022 to primary completion in Apr 2023, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MIVI Neuroscience, Inc.